• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4833721)   Today's Articles (5709)
For: Zhang D, Li S, Zhang X, Peng J, Zhang S. What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China. Front Oncol 2022;12:955124. [PMID: 36059631 PMCID: PMC9433773 DOI: 10.3389/fonc.2022.955124] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2022] [Accepted: 07/26/2022] [Indexed: 11/20/2022]  Open
Number Cited by Other Article(s)
1
Wang Y, Zhang J, Wu X, Huang L, Xiao W, Guo C. The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design. J Med Chem 2025;68:18-48. [PMID: 39723587 DOI: 10.1021/acs.jmedchem.4c02642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2024]
2
Afrăsânie VA, Rusu A, Gheorghe AS, Froicu EM, Dumitrescu EA, Gafton B, Alexa-Stratulat T, Miron L, Stănculeanu DL, Marinca MV. Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib. Diagnostics (Basel) 2024;14:1898. [PMID: 39272683 PMCID: PMC11394373 DOI: 10.3390/diagnostics14171898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2024] [Revised: 08/16/2024] [Accepted: 08/23/2024] [Indexed: 09/15/2024]  Open
3
Dong J, Ni J, Chen J, Wang X, Ye L, Xu X, Guo W, Chen X. Genomic alteration discordance in the paired primary-recurrent ovarian cancers: based on the comprehensive genomic profiling (CGP) analysis. J Ovarian Res 2024;17:133. [PMID: 38937827 PMCID: PMC11212203 DOI: 10.1186/s13048-024-01455-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2024] [Accepted: 06/13/2024] [Indexed: 06/29/2024]  Open
4
Uekusa R, Yokoi A, Watanabe E, Yoshida K, Yoshihara M, Tamauchi S, Shimizu Y, Ikeda Y, Yoshikawa N, Niimi K, Suzuki S, Kajiyama H. Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer. Cancer Med 2024;13:e7149. [PMID: 38572951 PMCID: PMC10993710 DOI: 10.1002/cam4.7149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 02/21/2024] [Accepted: 03/17/2024] [Indexed: 04/05/2024]  Open
5
Chen J, Zhang M, Li K, Duan Y, Lin X, Zhong L, Li Q, Yin R. A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China. Front Oncol 2024;13:1300199. [PMID: 38260846 PMCID: PMC10800576 DOI: 10.3389/fonc.2023.1300199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Accepted: 12/08/2023] [Indexed: 01/24/2024]  Open
6
Kim NK, Kim Y, Kim HS, Park SJ, Hwang DW, Lee SJ, Yoo JG, Chang S, Son J, Kong T, Kim J, Shim S, Lee AJ, Suh DH, Lee Y. Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004). Cancer Med 2023;12:19449-19459. [PMID: 37768030 PMCID: PMC10587974 DOI: 10.1002/cam4.6546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 04/24/2023] [Accepted: 09/05/2023] [Indexed: 09/29/2023]  Open
7
Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, Hashimoto H, Shimoi T, Yonemori K, Yonemura M, Terakado H, Nishimura T, Kawasaki T, Furukawa T, Nakamura T. Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study. Sci Rep 2023;13:11962. [PMID: 37488223 PMCID: PMC10366208 DOI: 10.1038/s41598-023-39224-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Accepted: 07/21/2023] [Indexed: 07/26/2023]  Open
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA